Please wait while we take you to your selected region.
ARA-290 is a synthetic peptide derived from erythropoietin (EPO) that selectively activates tissue-protective and anti-inflammatory pathways via innate repair receptor signaling, without stimulating red blood cell production.
It has been studied for its potential benefits in reducing inflammation, improving neuropathic pain, supporting wound healing, and modulating metabolic markers such as HbA1c and cholesterol, particularly in conditions related to diabetes and autoimmune disorders.
ARA-290 Overview
ARA-290 (cibinetide) is a synthetic peptide derived from erythropoietin (EPO) that selectively activates tissue-protective and anti-inflammatory pathways via the innate repair receptor (IRR), without stimulating red blood cell production.
Blood Vessel Protection and Repair
Research indicates that ARA-290 may support vascular repair by enhancing endothelial cell survival, migration, and regeneration. In preclinical studies, it has demonstrated protective effects against inflammation-induced vascular damage and may promote tissue recovery in ischemic conditions, including retinal injury.
Anti-Inflammatory and Immune Modulation
ARA-290 has been shown in animal studies to reduce pro-inflammatory cytokines such as IL-6, IL-12, and TNF-α by modulating macrophage and dendritic cell activity. This immune-regulating effect may help protect transplanted tissues, reduce inflammation, and support organ graft survival.
Tissue Protection and Regeneration
Preclinical research suggests that ARA-290 may enhance tissue repair by reducing inflammatory damage and improving cell survival. These effects have been observed in models of injury, including potential applications in diabetes-related complications and wound healing.
Neuropathic Pain Relief
ARA-290 has demonstrated potential in reducing neuropathic pain by acting on the innate repair receptor and modulating pain-related ion channels such as TRPV1. Studies suggest improvements in small fiber neuropathy, particularly in conditions like diabetes and sarcoidosis.
Clinical Research Status
ARA-290 has been investigated in clinical trials for conditions such as diabetic and sarcoid neuropathy and has received orphan drug designation for neuropathic pain related to sarcoidosis. Ongoing research continues to explore its therapeutic potential in inflammatory and autoimmune disorders.